Clinical Trial Goal
To find out:
- The highest dose of revumenib that’s safe to give with standard chemo
- If revumenib with standard chemo is safe and works well to treat AML that has not yet been treated
You may be able to join this trial if you:
- Are 18 - 75 years old
- Have AML that has not yet been treated
- Have cancer cells with one of the following mutations. Your doctor can tell you this:
- KMT2Ar
- NPM1c
- NUP98r
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cytarabine, daunorubicin and idarubicin are chemo drugs that block the growth of cancer cells.
Revumenib is a menin inhibitor that blocks interaction between the menin protein and the KMT2A protein.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Revumenib is a menin inhibitor that blocks interaction between the menin protein and the KMT2A protein.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Cytarabine and daunorubicin or idarubicin (standard chemo) – Given as intravenous (IV) infusions
- Revumenib - A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You may be eligible to continue treatment with a blood or marrow transplant (BMT) if you are eligible and have an available donor. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial to treat acute leukemia. Using them together in this way is new and unproven.
Locations
Sponsors
lead: Syndax Pharmaceuticals
